Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 15/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.72 |
| ▸ | DRD2 | P14416 | 1/20 | 0.72 |
| ▸ | ADRA1D | P25100 | 13/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 13/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764200 | 0.90 | ADRA1A (0.60) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL3986844 | 0.88 | ADRA1A (0.90) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7093811 | 0.86 | ADRA1A (0.75) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6672901 | 0.86 | ADRA1A (0.75) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL5660443 | 0.85 | ADRA1A (0.54) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| Snap-7941 SCHEMBL5658585 | 0.84 | ADRA1A (1.00) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6712292 | 0.82 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7093785 | 0.82 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL6710975 | 0.82 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B | |
| SCHEMBL7091765 | 0.82 | ADRA1A (0.79) | ADRA1AMCHR1DRD2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MARZABADI MOHAMMAD R | 2007-02-22 | — | — | US | disclosed |
| US-20050154022-A1 | 4-aryl piperidines | H. LUNDBECK A/S | 2005-07-14 | — | — | US | disclosed |
| US-6727264-B1 | MELANIN CONCENTRATING HORMONE-1 RECEPTOR ANTAGONISTS; SLEEP, EATING, SEXUAL DISORDERS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043080-A1 | Substituted anilinic piperidines as MCH selective antagonists | MCHR1, MCHR2, MC1R | ADRA1A 46/4885MCHR1 1/4885DRD2 119/4885 |
| US-20050154022-A1 | 4-aryl piperidines | MCHR1, MCHR2, MC1R | ADRA1A 39/4885MCHR1 1/4885DRD2 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.